KPL-387

Phase 2Recruiting
0 watching 0 views this week Active
47
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Recurrent Pericarditis

Conditions

Recurrent Pericarditis, Heart Diseases, Pericarditis

Trial Timeline

Jan 31, 2026 → Dec 31, 2029

About KPL-387

KPL-387 is a phase 2 stage product being developed by Kiniksa Pharmaceuticals for Recurrent Pericarditis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07288216. Target conditions include Recurrent Pericarditis, Heart Diseases, Pericarditis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT07288216Phase 2Recruiting

Competing Products

20 competing products in Recurrent Pericarditis

See all competitors
ProductCompanyStageHype Score
KPL-914Kiniksa PharmaceuticalsPhase 2
47
Rilonacept + PlaceboKiniksa PharmaceuticalsPhase 3
72
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
33
Zopapogene imadenovec (Zopa)PrecigenApproved
80
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2PrecigenPhase 1/2
36
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
Ramucirumab + PembrolizumabEli LillyPhase 2
52
Gemcitabine and UFTE chemotherapyYuhanPhase 2
52
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + PembrolizumabDaiichi SankyoPhase 1/2
41
Ifinatamab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab DeruxtecanDaiichi SankyoPhase 1
33
PLX3397Daiichi SankyoPhase 2
52
erlotinib + etoposideAstellas PharmaPhase 2
52
Drug Combination TherapySun PharmaceuticalPhase 2
52
Niraparib + AnlotinibSun PharmaceuticalPhase 2
52
Eribulin MesylateEisaiPre-clinical
23
Lenvatinib + EverolimusEisaiPhase 1/2
41
E7090EisaiPhase 2
52
LenvatinibEisaiPhase 2
52
Eribulin mesilate + Irinotecan hydrochlorideEisaiPhase 1/2
41